WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H535114
CAS#: 113558-89-7 (free)
Description: E 4031 is a class III anti-arrhythmia agent.
Hodoodo Cat#: H535114
Name: E 4031
CAS#: 113558-89-7 (free)
Chemical Formula: C21H27N3O3
Exact Mass: 401.18
Molecular Weight: 401.525
Elemental Analysis: C, 62.82; H, 6.78; N, 10.47; O, 11.95; S, 7.98
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 113558-89-7 (free); 113559-13-0 (dihydrochloride)
Synonym: E 4031; E-4031; E4031
IUPAC/Chemical Name: Methanesulfonamide, N-(4-((1-(2-(6-methyl-2-pyridinyl)ethyl)-4-piperidinyl)carbonyl)phenyl)-
InChi Key: SRUISGSHWFJION-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H27N3O3S/c1-16-4-3-5-19(22-16)12-15-24-13-10-18(11-14-24)21(25)17-6-8-20(9-7-17)23-28(2,26)27/h3-9,18,23H,10-15H2,1-2H3
SMILES Code: CS(=O)(NC1=CC=C(C(C2CCN(CCC3=NC(C)=CC=C3)CC2)=O)C=C1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 401.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Goto A, Izumi-Nakaseko H, Hagiwara-Nagasawa M, Chiba K, Ando K, Naito AT, Sugiyama A. Analysis of torsadogenic and pharmacokinetic profile of E-4031 in dogs bridging the gap of information between in vitro proarrhythmia assay and clinical observation in human subjects. J Pharmacol Sci. 2018 Jun;137(2):237-240. doi: 10.1016/j.jphs.2018.06.005. Epub 2018 Jun 18. PMID: 29980434.
2: E 4031. Drugs R D. 1999 Apr;1(4):312-6. doi: 10.2165/00126839-199901040-00006. PMID: 10566051.
3: Luo C, Wang K, Zhang H. Modelling the effects of quinidine, disopyramide, and E-4031 on short QT syndrome variant 3 in the human ventricles. Physiol Meas. 2017 Sep 21;38(10):1859-1873. doi: 10.1088/1361-6579/aa8695. PMID: 28812984.
4: Izumi D, Chinushi M, Iijima K, Ahara S, Komura S, Furushima H, Hosaka Y, Sanada A, Yagihara N, Aizawa Y. Effects of bepridil versus E-4031 on transmural ventricular repolarization and inducibility of ventricular tachyarrhythmias in the dog. Pacing Clin Electrophysiol. 2010 Aug;33(8):950-9. doi: 10.1111/j.1540-8159.2010.02768.x. Epub 2010 May 4. PMID: 20487341.
5: Kim I, Boyle KM, Carroll JL. Postnatal development of E-4031-sensitive potassium current in rat carotid chemoreceptor cells. J Appl Physiol (1985). 2005 Apr;98(4):1469-77. doi: 10.1152/japplphysiol.01254.2003. Epub 2004 Dec 10. PMID: 15591286.
6: Ishii K, Nagai M, Takahashi M, Endoh M. Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency. Cardiovasc Res. 2003 Mar;57(3):651-9. doi: 10.1016/s0008-6363(02)00774-5. PMID: 12618227.
7: Ziupa D, Beck J, Franke G, Perez Feliz S, Hartmann M, Koren G, Zehender M, Bode C, Brunner M, Odening KE. Pronounced effects of HERG-blockers E-4031 and erythromycin on APD, spatial APD dispersion and triangulation in transgenic long-QT type 1 rabbits. PLoS One. 2014 Sep 22;9(9):e107210. doi: 10.1371/journal.pone.0107210. PMID: 25244401; PMCID: PMC4170956.
8: Nikmaram MR, Liu J, Abdelrahman M, Dobrzynski H, Boyett MR, Lei M. Characterization of the effects of ryanodine, TTX, E-4031 and 4-AP on the sinoatrial and atrioventricular nodes. Prog Biophys Mol Biol. 2008 Jan- Apr;96(1-3):452-64. doi: 10.1016/j.pbiomolbio.2007.07.003. Epub 2007 Aug 1. PMID: 17850852.
9: Luo C, Wang K, Zhang H. In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles. PLoS One. 2017 Jun 20;12(6):e0179515. doi: 10.1371/journal.pone.0179515. PMID: 28632743; PMCID: PMC5478111.
10: Bai XJ, Hao JT. [Effects of E 4031 on isolated cardiac function and resting Ca2+ level of myocardial cells from rats with chronic heart failure]. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2014 Jul;30(4):364-7. Chinese. PMID: 25330678.
11: Katoh H, Ogawa S, Furuno I, Sato Y, Yoh S, Saeki K, Nakamura Y. Electrophysiologic effects of E-4031, a class III antiarrhythmic agent, on re- entrant ventricular arrhythmias in a canine 7-day-old myocardial infarction model. J Pharmacol Exp Ther. 1990 Jun;253(3):1077-82. PMID: 2359016.
12: Nagashima Y, Furukawa Y, Hirose M, Hoyano Y, Lakhe M, Chiba S. Inhibition by E-4031 of the prolongation of the first returning cycle length after overdrive in anesthetized dog hearts. J Cardiovasc Pharmacol. 1998 Jan;31(1):18-24. doi: 10.1097/00005344-199801000-00003. PMID: 9456272.
13: Michael G, Dempster J, Kane KA, Coker SJ. Potentiation of E-4031-induced torsade de pointes by HMR1556 or ATX-II is not predicted by action potential short-term variability or triangulation. Br J Pharmacol. 2007 Dec;152(8):1215-27. doi: 10.1038/sj.bjp.0707513. Epub 2007 Oct 29. PMID: 17965747; PMCID: PMC2189990.
14: Yamazaki K, Furukawa Y, Kasama M, Imamura H, Chiba S. Negative chronotropic and dromotropic effects of E-4031, an IKr blocker, on the atrioventricular node in anesthetized dog hearts. Eur J Pharmacol. 1996 Feb 22;297(3):233-9. doi: 10.1016/0014-2999(95)00753-9. PMID: 8666055.
15: Cheng J, Kamiya K, Kodama I, Toyama J. Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes. Cardiovasc Res. 1996 Jun;31(6):963-74. PMID: 8759253.
16: Ogawa S, Mitamura H, Katoh H. Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs. Cardiovasc Drugs Ther. 1993 Aug;7 Suppl 3:621-6. doi: 10.1007/BF00877629. PMID: 8251432.
17: Weinsberg F, Bauer CK, Schwarz JR. The class III antiarrhythmic agent E-4031 selectively blocks the inactivating inward-rectifying potassium current in rat anterior pituitary tumor cells (GH3/B6 cells). Pflugers Arch. 1997 May;434(1):1-10. doi: 10.1007/s004240050356. PMID: 9094250.
18: Goldfracht I, Efraim Y, Shinnawi R, Kovalev E, Huber I, Gepstein A, Arbel G, Shaheen N, Tiburcy M, Zimmermann WH, Machluf M, Gepstein L. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications. Acta Biomater. 2019 Jul 1;92:145-159. doi: 10.1016/j.actbio.2019.05.016. Epub 2019 May 7. PMID: 31075518.
19: Bril A, Landais L, Gout B. Actions and interactions of E-4031 and tedisamil on reperfusion-induced arrhythmias and QT interval in rat in vivo. Cardiovasc Drugs Ther. 1993 Apr;7(2):233-40. doi: 10.1007/BF00878513. PMID: 8357777.
20: Izumi-Nakaseko H, Nakamura Y, Cao X, Ohara H, Yamazaki Y, Ueda N, Ando K, Sugiyama A. Effects of selective IKr channel blockade by E-4031 on ventricular electro-mechanical relationship in the halothane-anesthetized dogs. Eur J Pharmacol. 2014 Oct 5;740:263-70. doi: 10.1016/j.ejphar.2014.06.064. Epub 2014 Jul 17. PMID: 25038475.
